These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23222095)

  • 1. A comparison of buprenorphine taper outcomes between prescription opioid and heroin users.
    Nielsen S; Hillhouse M; Thomas C; Hasson A; Ling W
    J Addict Med; 2013; 7(1):33-8. PubMed ID: 23222095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.
    Sigmon SC; Dunn KE; Saulsgiver K; Patrick ME; Badger GJ; Heil SH; Brooklyn JR; Higgins ST
    JAMA Psychiatry; 2013 Dec; 70(12):1347-54. PubMed ID: 24153411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterizing opioid withdrawal during double-blind buprenorphine detoxification.
    Dunn KE; Saulsgiver KA; Miller ME; Nuzzo PA; Sigmon SC
    Drug Alcohol Depend; 2015 Jun; 151():47-55. PubMed ID: 25823907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.
    Fiellin DA; Schottenfeld RS; Cutter CJ; Moore BA; Barry DT; O'Connor PG
    JAMA Intern Med; 2014 Dec; 174(12):1947-54. PubMed ID: 25330017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.
    Weiss RD; Potter JS; Fiellin DA; Byrne M; Connery HS; Dickinson W; Gardin J; Griffin ML; Gourevitch MN; Haller DL; Hasson AL; Huang Z; Jacobs P; Kosinski AS; Lindblad R; McCance-Katz EF; Provost SE; Selzer J; Somoza EC; Sonne SC; Ling W
    Arch Gen Psychiatry; 2011 Dec; 68(12):1238-46. PubMed ID: 22065255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of buprenorphine initial outpatient maintenance and dose taper response among non-treatment-seeking heroin dependent volunteers.
    Woodcock EA; Lundahl LH; Greenwald MK
    Drug Alcohol Depend; 2015 Jan; 146():89-96. PubMed ID: 25479914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine pharmacotherapy and behavioral treatment: comparison of outcomes among prescription opioid users, heroin users and combination users.
    Nielsen S; Hillhouse M; Mooney L; Ang A; Ling W
    J Subst Abuse Treat; 2015 Jan; 48(1):70-6. PubMed ID: 25065489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buprenorphine tapering schedule and illicit opioid use.
    Ling W; Hillhouse M; Domier C; Doraimani G; Hunter J; Thomas C; Jenkins J; Hasson A; Annon J; Saxon A; Selzer J; Boverman J; Bilangi R
    Addiction; 2009 Feb; 104(2):256-65. PubMed ID: 19149822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing buprenorphine induction experience with heroin and prescription opioid users.
    Nielsen S; Hillhouse M; Mooney L; Fahey J; Ling W
    J Subst Abuse Treat; 2012 Oct; 43(3):285-90. PubMed ID: 22301084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Participant characteristics and buprenorphine dose.
    Hillhouse M; Canamar CP; Doraimani G; Thomas C; Hasson A; Ling W
    Am J Drug Alcohol Abuse; 2011 Sep; 37(5):453-9. PubMed ID: 21854290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between opioid cross-tolerance during buprenorphine stabilization and return to opioid use during buprenorphine dose tapering.
    Greenwald MK; Sogbesan T; Moses TEH
    Psychopharmacology (Berl); 2024 Jun; 241(6):1151-1160. PubMed ID: 38326506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The multi-site prescription opioid addiction treatment study: 18-month outcomes.
    Potter JS; Dreifuss JA; Marino EN; Provost SE; Dodd DR; Rice LS; Fitzmaurice GM; Griffin ML; Weiss RD
    J Subst Abuse Treat; 2015 Jan; 48(1):62-9. PubMed ID: 25189089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START).
    Potter JS; Marino EN; Hillhouse MP; Nielsen S; Wiest K; Canamar CP; Martin JA; Ang A; Baker R; Saxon AJ; Ling W
    J Stud Alcohol Drugs; 2013 Jul; 74(4):605-13. PubMed ID: 23739025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective analysis of heroin detoxification with buprenorphine in a psychiatric hospital in Japan.
    Nagano T; Kimoto S; Aso K; Komori T; Yamaguchi Y; Okamura K; Yamamoto N; Kishimoto T
    Neuropsychopharmacol Rep; 2020 Dec; 40(4):376-382. PubMed ID: 33107693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine-naloxone treatment responses differ between young adults with heroin and prescription opioid use disorders.
    Romero-Gonzalez M; Shahanaghi A; DiGirolamo GJ; Gonzalez G
    Am J Addict; 2017 Dec; 26(8):838-844. PubMed ID: 29143399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
    Worley MJ; Heinzerling KG; Shoptaw S; Ling W
    Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lifetime history of heroin use is associated with greater drug severity among prescription opioid abusers.
    Meyer AC; Miller ME; Sigmon SC
    Addict Behav; 2015 Mar; 42():189-93. PubMed ID: 25481453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model.
    Northrup TF; Stotts AL; Green C; Potter JS; Marino EN; Walker R; Weiss RD; Trivedi M
    Addict Behav; 2015 Feb; 41():20-8. PubMed ID: 25282598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic.
    O'Connor PG; Oliveto AH; Shi JM; Triffleman EG; Carroll KM; Kosten TR; Rounsaville BJ; Pakes JA; Schottenfeld RS
    Am J Med; 1998 Aug; 105(2):100-5. PubMed ID: 9727815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers.
    Comer SD; Sullivan MA; Vosburg SK; Manubay J; Amass L; Cooper ZD; Saccone P; Kleber HD
    Addiction; 2010 Apr; 105(4):709-18. PubMed ID: 20403021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.